Comparison of the Prognostic Value of Ki-67 and Programmed Cell Death Ligand-1 in Patients with Upper Tract Urothelial Carcinoma

We retrospectively enrolled 102 patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy to examine the prognostic value of Ki-67 and programmed cell death ligand-1 (PD-L1). Then, we performed PD-L1 and Ki-67 immunohistochemical staining on whole tissue sections. The cut-off value of PD-L1 positivity was a combined positive score (CPS) ≥10 and the Ki-67 overexpression was 20%. Among the 102 patients, 16.7% and 48.0% showed positive PD-L1 expression and Ki-67 overexpression, respectively. A CPS ≥10 was significantly associated with a higher pathological T stage (p = 0.049). In addition, Ki-67 overexpression was significantly associated with a pathological T stage ≥ 2 (p = 0.027) and tumour necrosis (p = 0.016). In the multivariable analysis, a positive PD-L1 expression was significantly correlated with worse cancer-specific survival (HR = 3.66, 95% CI =1.37−9.77, p = 0.01). However, there was no predictive value using a combination of PD-L1 expression and Ki-67 overexpression as a prognostic predictor. Compared with Ki-67 overexpression, a positive PD-L1 expression with CPS ≥ 10 was a stronger independent prognostic factor for CSS in patients with UTUC.

[1]  E. Tsai,et al.  Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma , 2021, Cancer Immunology, Immunotherapy.

[2]  J. Pow-Sang,et al.  Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study , 2020, World Journal of Urology.

[3]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.

[4]  C. Ohyama,et al.  Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan‐Japan UTUC Collaboration Cohort , 2020, International journal of urology : official journal of the Japanese Urological Association.

[5]  Y. Lotan,et al.  Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. , 2019, Urologic oncology.

[6]  Qiaochao Chen,et al.  Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis , 2019, Cancer management and research.

[7]  H. Kume,et al.  The prognostic value of PD‐L1 expression in upper tract urothelial carcinoma varies according to platelet count , 2018, Cancer medicine.

[8]  K. Bensalah,et al.  Prognostic Value of PD‐1 and PD‐L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma , 2017, The Journal of urology.

[9]  Hong Zhang,et al.  Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma , 2017, Medical Oncology.

[10]  J. Lunceford,et al.  Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. , 2017, The Lancet. Oncology.

[11]  A. Chinnaiyan,et al.  Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. , 2016, European urology focus.

[12]  N. Lawrentschuk,et al.  Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review , 2017, World Journal of Urology.

[13]  Chin-Li Lu,et al.  Chronic kidney disease is associated with upper tract urothelial carcinoma – A nationwide population-based cohort study in Taiwan , 2016 .

[14]  Shengjie Liu,et al.  Low-level Ki-67 expression as an independent predictor of bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy. , 2015, Japanese journal of clinical oncology.

[15]  K. Bensalah,et al.  Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. , 2015, The Journal of urology.

[16]  Jing-Shiang Hwang,et al.  Increased Upper and Lower Tract Urothelial Carcinoma in Patients with End-Stage Renal Disease: A Nationwide Cohort Study in Taiwan during 1997–2008 , 2014, BioMed research international.

[17]  Y. Lotan,et al.  Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. , 2014, The Journal of urology.

[18]  C. Shun,et al.  Aristolochic acid‐induced upper tract urothelial carcinoma in Taiwan: Clinical characteristics and outcomes , 2013, International journal of cancer.

[19]  Felicia Wu,et al.  Risk Assessment of Upper Tract Urothelial Carcinoma Related to Aristolochic Acid , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[20]  Pau-Chung Chen,et al.  Increased risks of upper tract urothelial carcinoma in male and female chinese herbalists. , 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.

[21]  J. W. Lee,et al.  Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. , 2010, Urology.

[22]  F. Montorsi,et al.  Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. , 2010, The Journal of urology.

[23]  U. Capitanio,et al.  Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. , 2009, Journal of the National Cancer Institute.

[24]  H. Kuo,et al.  Upper urinary tract urothelial carcinoma in eastern Taiwan: high proportion among all urothelial carcinomas and correlation with chronic kidney disease. , 2007, Journal of the Formosan Medical Association = Taiwan yi zhi.

[25]  Y. Lotan,et al.  Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease , 2006, Clinical Cancer Research.

[26]  T. Igarashi,et al.  The prognostic value of p53, Ki‐67 and matrix metalloproteinases MMP‐2 and MMP‐9 in transitional cell carcinoma of the renal pelvis and ureter , 2005, International journal of urology : official journal of the Japanese Urological Association.

[27]  Jin-Hwang Liu,et al.  Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. , 2002, Urology.

[28]  Y. H. Lee,et al.  The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. , 2000, The Journal of urology.